Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more
Ningbo MedicalSystem Biotechnology Co Ltd (300439) - Total Liabilities
Latest total liabilities as of September 2025: CN¥706.76 Million CNY
Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has total liabilities worth CN¥706.76 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ningbo MedicalSystem Biotechnology Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
USA | $13.54 Million |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
USA | $10.14 Million |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
India | ₹15.63 Billion |
|
Dareway Software Co Ltd
SHG:688579
|
China | CN¥249.17 Million |
|
Checkpoint Therapeutics Inc
NASDAQ:CKPT
|
USA | $17.87 Million |
|
Bumble Inc
NASDAQ:BMBL
|
USA | $1.16 Billion |
|
Flughafen Wien Aktiengesellschaft
PINK:FGWLF
|
USA | $710.15 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ningbo MedicalSystem Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual total liabilities of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥771.65 Million | -1.39% |
| 2023-12-31 | CN¥782.49 Million | -26.47% |
| 2022-12-31 | CN¥1.06 Billion | -11.49% |
| 2021-12-31 | CN¥1.20 Billion | -23.27% |
| 2020-12-31 | CN¥1.57 Billion | -33.38% |
| 2019-12-31 | CN¥2.35 Billion | +1.09% |
| 2018-12-31 | CN¥2.33 Billion | +16.84% |
| 2017-12-31 | CN¥1.99 Billion | +25.27% |
| 2016-12-31 | CN¥1.59 Billion | +897.74% |
| 2015-12-31 | CN¥159.36 Million | -22.69% |
| 2014-12-31 | CN¥206.12 Million | +26.77% |
| 2013-12-31 | CN¥162.59 Million | +26.38% |
| 2012-12-31 | CN¥128.66 Million | +88.31% |
| 2011-12-31 | CN¥68.32 Million | -- |